Abstract

Although sedation interruption in the intensive care unit (ICU) is recommended in the literature for adults, its place in paediatrics has been much debated. The arguments for not using sedation interruption protocols include the danger of extubation, ventilator- associated pneumonia, safety, comfort and, most importantly, synchronisation with the ventilator. �ere are also conicting reports and a poor evidence base for the use of this strategy, with only two published randomised controlled trials comparing daily sedation interruption and protocolised sedation. An article by Vet et al. (1) presented the results of a multicentre, randomised controlled trial in the Netherlands on this much-debated issue. �e aim of their study was to compare daily sedation interruption plus protocolised sedation (DSI�+�PS) with protocolised sedation (PS) only in critically ill children. �ey excluded premature neonates born at <37 weeks gestational age and children with cardiac, neurological or respiratory conditions who would not tolerate inadequate sedation. How this was determined is unclear and is an important confounder in this study, as only 132 (12%) of 1 059 patients screened over a 5-year period could be assigned to the intervention arm of either DSI�+�PS (n=66) or PS (n=63). Unfortunately, the study was terminated prior to the expected recruitment total of 200 patients because of low recruitment rates, making the interpretation of the results - using a primary endpoint of number of ventilator-free days at day�28 - dicult. �eir results showed no dierence in ventilator-free days; 24.0�days in both groups. �e median ICU and hospital length of stay were similar in both groups: DSI�+�PS 6.9�days (interquartile range (IQR) 5.2 - 11.0) v. PS 7.4�days (IQR 5.3 - 12.8) (p=0.47), and DSI�+�PS 13.3�days (IQR 8.6 - 26.7) v. PS 15.7 days (IQR 9.3 - 33.2) (p=0.19). Mortality at 30�days was higher in the DSI�+�PS group than in the PS group (6/66 v. 0/63, respectively, p=0.03), though no causal relationship with the intervention could be established. �e median cumulative midazolam dose did not dier: DSI�+�PS 14.1�mg/kg (IQR 7.6 - 22.6) v. PS 17.0�mg/kg (IQR 8.2 - 39.8) (p=0.11). This surprising finding of increased mortality could not be explained by the authors but is a signal of possible harm as a result of drug interruption in children, in contrast to the experience among adults. �us, DSI in the paediatric ICU is currently not recommended, as the adverse eects are well known and should be minimised and avoided.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.